Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022. Highlights A strong first-quarter total-sales performance, with growth of 9.6% at CER 1 (12.5% as r...
A committee of the European Medicines Agency (EMA) recommended the approval of expanded use of Ipsen (OTCPK:IPSEF) (OTCPK:IPSEY) and Exelixis' (NASDAQ:EXEL) Cabometyx as a standalone therapy for certain patients with differentiated thyroid cancer (DTC). The positive opinio...
Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx ® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo 1 Disclaimer: Intended for international media and investor audiences only ...
Ipsen (OTCPK:IPSEF) (OTCPK:IPSEF) said it will invest ~€60M for a new fourth generation electronic autoinjector for Somatuline Autogel/ Somatuline Depot (lanreotide) and in its Signes manufacturing site in France. New electronic autoinjector is designed to improve patient experien...
New electronic autoinjector is designed to improve patient experience for people living with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome or acromegaly Performance and safety studies ongoing, with first launches for the new device expected in 2024 A fourth ...
Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for a...
Ipsen (OTCPK:IPSEF) (OTCPK:IPSEY) reported data from PRESTO 2 and HomeLAN surveys which showed patient-reported benefits when administering Somatuline Autogel/Somatuline Depot (lanreotide). Somatuline Depot is used to treat gastroenteropancreatic neuroendocrine tumors...
New data presented at ENETS 2022 showed patients treated with Somatuline ® Autogel ® /Somatline ® Depot (lanreotide) pre-filled syringe reported less frequent injection-site pain lasting more than two days than those treated with octreotide long-acting relea...
Ipsen (OTCPK:IPSEF) said two-year follow-up data from a phase 3 CheckMate -9ER trial, showed sustained survival benefits, and health related quality of life (HRQoL) improvements with the combination of Exelixis (NASDAQ:EXEL) Cabometyx (cabozantinib) and Bristol-Myers Squib...
Updated results to be presented at ASCO GU 2022 showed sustained efficacy and tumor shrinkage benefits with Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) compared to sunitinib 1 People living with advanced renal cell carcinoma treated with the combination con...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...